Emerging Multimodality Approaches to Treat Localized Esophageal Cancer

Restricted access

Esophageal cancer has a poor prognosis, with 5-year survival rates ranging from 20% to 35% in the nonmetastatic setting. Despite advances in surgical techniques and optimization of chemoradiotherapy regimens, overall survival benefits have been incremental at best. Esophageal cancer requires a concerted multidisciplinary approach, perhaps more so than any other tumor type given the integral role played by the esophagus in maintaining calorific intake and the propensity for early spread through the lymphatics. This review describes the latest in surgical techniques to minimize postoperative complications and examines previous and ongoing systemic therapy approaches. Strategies that harness a patient’s own immune system hold great promise, and shifting checkpoint inhibitors from the metastatic setting to the neoadjuvant/adjuvant setting is currently being evaluated in phase II and III clinical trials. In addition, a much better understanding of the interplay between tumors and their immune microenvironment is clearly needed to better judge how best to engage each patient’s immune system, and there will be likely demonstrable differences between early-stage tumors and metastatic disease. This review highlights emerging data, which demonstrate that, in addition to The Cancer Genome Atlas classification of esophageal squamous cell carcinoma having a distinct molecular makeup compared with esophageal adenocarcinoma, there are also differing responses to PD-1 inhibitors. Histology and the underlying immune milieu may have important ramifications for the management of localized disease in the future, above and beyond PD-L1 expression, microsatellite instability status, and tumor mutational burden.

Submitted May 16, 2019; accepted for publication June 27, 2019.Disclosures: Dr. Kelly has disclosed that he has served on advisory boards for Bristol Myers-Squibb, Eli Lilly, Novartis, AstraZeneca, and Merck; has received grant/research support from Bristol Myers-Squibb, Eli Lilly, and AstraZeneca; and has worked as a consultant for Cardinal Health.Correspondence: Ronan J. Kelly, MD, MBA, Charles A. Sammons Cancer Center at Baylor University Medical Center, 3410 Worth Street, Suite 550, Dallas, TX 75246. Email: Ronan.Kelly@BSWHealth.org
  • 1.

    Bray F, Ferlay J, Soerjomataram I, . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 2.

    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017;67:7–30.

  • 3.

    Napier KJ, Scheerer M, Misra S. Esophageal cancer: a review of epidemiology, pathogenesis, staging workup and treatment modalities. World J Gastrointest Oncol 2014;6:112–120.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Amin M, Edge S, Green F, , eds. AJCC Cancer Staging Manual, 8th ed. Cham, Switzerland: Springer International Publishing; 2017.

  • 5.

    Cancer Genome Atlas Network, Analysis Working Group: Asian University, BC Cancer Agency, . Integrated genomic characterization of oesophageal carcinoma. Nature 2017;541:169–175.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Pasquer A, Renaud F, Hec F, . Is centralization needed for esophageal and gastric cancer patients with low operative risk?: a nationwide study. Ann Surg 2016;264:823–830.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7.

    van Hagen P, Hulshof MC, van Lanschot JJ, . Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012;366:2074–2084.

  • 8.

    Biere SS, van Berge Henegouwen MI, Maas KW, . Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. Lancet 2012;379:1887–1892.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Mariette C, Markar SR, Dabakuyo-Yonli TS, . Hybrid minimally invasive esophagectomy for esophageal cancer. N Engl J Med 2019;380:152–162.

  • 10.

    Kelsen DP, Winter KA, Gunderson LL, . Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol 2007;25:3719–3725.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Allum WH, Stenning SP, Bancewicz J, . Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 2009;27:5062–5067.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Kelsen DP, Ginsberg R, Pajak TF, . Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998;339:1979–1984.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Macdonald JS, Smalley SR, Benedetti J, . Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725–730.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002;359:1727–1733.

    • Search Google Scholar
    • Export Citation
  • 15.

    Cunningham D, Allum WH, Stenning SP, . Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11–20.

  • 16.

    Stahl M, Walz MK, Stuschke M, . Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009;27:851–856.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Stahl M, Walz MK, Riera-Knorrenschild J, . Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): long-term results of a controlled randomised trial. Eur J Cancer 2017;81:183–190.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Ychou M, Boige V, Pignon JP, . Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011;29:1715–1721.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Klevebro F, Alexandersson von Döbeln G, Wang N, . A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction. Ann Oncol 2016;27:660–667.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Al-Batran S, Pauligk C, Homann N, . Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) for resectable esophagogastric cancer: updated results from multicenter, randomized phase 3 FLOT3 FLOT4-AIO trial (German Gastric Group at AIO). Ann Oncol 2017;28(Suppl 5):v605–649.

    • Search Google Scholar
    • Export Citation
  • 21.

    Alderson D, Cunningham D, Nankivell M, . Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial. Lancet Oncol 2017;18:1249–1260.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    Cunningham D, Stenning SP, Smyth EC, . Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial. Lancet Oncol 2017;18:357–370.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23.

    Ajani JA, D’Amico TA, Bentrem DJ, . Esophageal and Esophagogastric Junction Cancers. Version 2.2019. Accessed June 29, 2019. To view the most recent version, visit NCCN.org.

  • 24.

    Shapiro J, van Lanschot JJB, Hulshof MCCM, . Neoadjuvant chemoradiotherapy plus surgery versus surgery alone fInsert or oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 2015;16:1090–1098.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 25.

    Nakamura K, Kato K, Igaki H, . Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT study). Jpn J Clin Oncol 2013;43:752–755.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26.

    Shah MA, Kojima T, Hochhauser D, . Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: the phase 2 KEYNOTE-180 study [published online December 20, 2018]. JAMA Oncol, doi: 10.1001/jamaoncol.2018.5441

    • Search Google Scholar
    • Export Citation
  • 27.

    Kojima T, Hara H, Yamaguchi K, . Phase II study of nivolumab (ONO-4538/BMS-936558) in patients with esophageal cancer: preliminary report of overall survival [abstract]. J Clin Oncol 2016;34(Suppl):Abstract TPS175.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 28.

    Kojima T, Muro K, Francois E, . Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: phase III KEYNOTE-181 study [abstract]. J Clin Oncol 2019;37(Suppl 4):Abstract 2.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 29.

    Nivolumab demonstrates a significant extension in overall survival versus chemotherapy in patients with unresectable advanced or recurrent esophageal cancer [press release]. Osaka, Japan; Ono Pharmaceutical Co., Ltd; January 10, 2019.

  • 30.

    Wu C, Zhu Y, Jiang J, . Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem 2006;108:19–24.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31.

    Hou J, Yu Z, Xiang R, . Correlation between infiltration of FOXP3+ regulatory T cells and expression of B7-H1 in the tumor tissues of gastric cancer. Exp Mol Pathol 2014;96:284–291.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32.

    Geng Y, Wang H, Lu C, . Expression of costimulatory molecules B7-H1, B7-H4 and Foxp3+ Tregs in gastric cancer and its clinical significance. Int J Clin Oncol 2015;20:273–281.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33.

    Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014;513:202–209.

  • 34.

    Le DT, Uram JN, Wang H, . PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372:2509–2520.

  • 35.

    Ku G, Lee J, Heinz-Josef L, . Safety and efficacy of durvalumab in combination with tremelimumab in patients with advanced gastric cancer with elevated tumor interferon-y gene signature. Presented at the 2019 AACR Annual Meeting; March 29–April 3, 2019; Atlanta, GA. Abstract CT057/014.

  • 36.

    Fuchs CS, Doi T, Jang RW, . Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol 2018;4:e180013.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 37.

    Li Z, Shan F, Wang Y, . Correlation of pathological complete response with survival after neoadjuvant chemotherapy in gastric or gastroesophageal junction cancer treated with radical surgery: a meta-analysis. PLoS One 2018;13:e0189294.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 38.

    Kelly RJ, Lockhart AC, Jonker DJ, . CheckMate 577: a randomized, double-blind, phase 3 study of nivolumab (NIVO) or placebo in patients (Pts) with resected lower esophageal (LE) or gastroesophageal junction (GEJ) cancer [abstract]. J Clin Oncol 2017;35(Suppl 4):Abstract TPS212.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 39.

    Bang YJ, Van Cutsem E, Fuchs CS, . KEYNOTE-585: phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer. Future Oncol 2019;15:943–952.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 40.

    Al-Batran SE, Hofheinz RD, Pauligk C, . Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol 2016;17:1697–1708.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 41.

    Thompson ED, Zahurak M, Murphy A, . Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. Gut 2017;66:794–801.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 42.

    Kelly RJ, Zaidi AH, Smith MA, . The dynamic and transient immune microenvironment in locally advanced esophageal adenocarcinoma post chemoradiation. Ann Surg 2018;268:992–999.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 43.

    Kelly RJ, Smith KN, Anagnostou V, . Neoadjuvant nivolumab plus concurrent chemoradiation in stage II/III esophageal/gastroesophageal junction cancer [abstract]. J Clin Oncol 2019;37(Suppl):Abstract 142.

    • Crossref
    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1149 1149 104
PDF Downloads 377 377 36
EPUB Downloads 0 0 0